Reasons for ineligibility for clinical trials of patients with medication-resistant epilepsy

Wesley T Kerr1, Hai Chen2,3,4, Mariana Figuera Losada2

  • 1Department of Neurology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.

Epilepsia
|March 4, 2023
PubMed

Insights

Recruiting for medication-resistant epilepsy clinical trials is difficult. This study found only 9.4% of patients met trial criteria, with low seizure frequency being the main exclusion reason.

Area of Science:

  • Neurology
  • Clinical Trials
  • Epilepsy Research

Background:

  • Clinical trials for medication-resistant epilepsy (MRE) use strict selection criteria to ensure safety and reduce variability.
  • Recruitment for these trials has become increasingly challenging.

Purpose of the Study:

  • To investigate the impact of inclusion and exclusion criteria on MRE clinical trial recruitment.
  • To determine the proportion of eligible patients and common reasons for exclusion at a major academic epilepsy center.

Main Methods:

  • Retrospective analysis of patients with MRE (focal or generalized onset) attending an outpatient clinic over three months.
  • Assessment of patient eligibility for clinical trials based on common inclusion/exclusion criteria.
  • Identification of the most frequent reasons for patient exclusion.

Main Results:

  • Out of 212 patients with MRE, only 9.4% (20 patients) were eligible for clinical trials.
  • Insufficient seizure frequency was the primary reason for exclusion, affecting 58% of focal onset and 55% of generalized onset epilepsy patients.
  • Only 19 focal onset and 1 generalized onset epilepsy patients met the eligibility criteria.

Conclusions:

  • A small fraction of MRE patients meet eligibility criteria for clinical trials.
  • Eligible patients may not represent the broader MRE population.
  • Insufficient seizure frequency is a significant barrier to MRE clinical trial recruitment.

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
235
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
236
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
386
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
457
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
180
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
512